Multiple endocrine neoplasia type 1 classification

Jump to navigation Jump to search

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 classification

CDC on Multiple endocrine neoplasia type 1 classification

Multiple endocrine neoplasia type 1 classification in the news

Blogs on Multiple endocrine neoplasia type 1 classification

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2] Ajay Gade MD[3]]

Overview

MEN-1 syndrome encompasses entero-pancreatic tumors, pituitary adenoma, parathyroid adenoma and other associated tumors such as adrenal cortical tumor, pheochromocytoma, bronchopulmonary (neuroendocrine tumor) NET, thymic NET, gastric NET, lipomas, angiofibromas, collagenomas and meningiomas.

Classification

MEN-1 syndrome encompasses entero-pancreatic tumors, pituitary adenoma, parathyroid adenoma and other associated tumors.[1][2][3][4][5][6][7][8]

Multiple Endocrine Neoplasia-1 (MEN-1) Syndrome Tumors
Enteropancreatic tumor
Pituitary adenoma
Associated tumors
Parathyroid adenoma

-

References

  1. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML (2012). "Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)". J. Clin. Endocrinol. Metab. 97 (9): 2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327.
  2. Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S, Peracchi M, D'Agruma L, Minisola S, Corbetta S, Cole DE, Spada A, Scillitani A (2009). "Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity". J. Bone Miner. Res. 24 (8): 1404–10. doi:10.1359/jbmr.090304. PMID 19309299.
  3. Vergès B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A (2002). "Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study". J. Clin. Endocrinol. Metab. 87 (2): 457–65. doi:10.1210/jcem.87.2.8145. PMID 11836268.
  4. Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE, Polak JM, Häcki WH, Stamm B, Heitz PU (1990). "Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome". N. Engl. J. Med. 322 (11): 723–7. doi:10.1056/NEJM199003153221103. PMID 1968616.
  5. Anlauf M, Garbrecht N, Henopp T, Schmitt A, Schlenger R, Raffel A, Krausch M, Gimm O, Eisenberger CF, Knoefel WT, Dralle H, Komminoth P, Heitz PU, Perren A, Klöppel G (2006). "Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features". World J. Gastroenterol. 12 (34): 5440–6. PMC 4088224. PMID 17006979.
  6. Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S, Johnson PR, Phillips RR, Ryan FJ, Shine B, Bowl MR, Thakker RV (2009). "Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors". J. Clin. Endocrinol. Metab. 94 (10): 3640–6. doi:10.1210/jc.2009-0564. PMID 19622622.
  7. Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, Lévy-Bohbot N, du Boullay H, Bertagna X, Ruszniewski P, Borson-Chazot F, Vergès B, Sadoul JL, Ménégaux F, Tabarin A, Kühn JM, d'Anella P, Chabre O, Christin-Maitre S, Cadiot G, Binquet C, Delemer B (2015). "MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines". J. Clin. Endocrinol. Metab. 100 (4): 1568–77. doi:10.1210/jc.2014-3659. PMID 25594862.
  8. Teh BT, McArdle J, Chan SP, Menon J, Hartley L, Pullan P, Ho J, Khir A, Wilkinson S, Larsson C, Cameron D, Shepherd J (1997). "Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1". Medicine (Baltimore). 76 (1): 21–9. PMID 9064485.

Template:WS Template:WH